Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Babu, Anish ^a,b   Amreddy, Narsireddy ^a,b   Muralidharan, Ranganayaki ^a,b   Pathuri, Gopal ^a,b   Gali, Hariprasad ^b   Chen, Allshine ^b   Zhao, Yan D ^b   Munshi, Anupama ^a,b   Ramesh, Rajagopal ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHITOSAN; NANOPARTICLE; PACLITAXEL; VITRONECTIN RECEPTOR;

A-549 CELL LINE; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; LUNG TUMOR; PROCEDURES; TUMOR CELL LINE;

A549 CELLS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; NANOPARTICLES; PACLITAXEL; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

EID: 85033410286     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-15012-5     Document Type: Article

References (75)

1. Ozkok, A. & Edelstein, C. L. Pathophysiology of Cisplatin-Induced Acute Kidney Injury. Bio Med Res Int. 2014, 967826, https://doi.org/10.1155/2014/967826 (2014).
2. Volkova, M. & Russell, R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev. 7, 214-220 (2011).
3. Ferrarotto, R., Schetino, G., Freitas, D., Capelozzi, V. & Hoff, P. M. Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature. Oncol Rev. 4, 101-106 (2010).
4. Charpidou, A. G. et al. Therapy-induced Toxicity of the Lungs: An Overview. Anticancer Res. 29, 631-639 (2009).
5. Aravind, A. et al. Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer Nanotechnol. 3, 1-12 (2012).
6. Amreddy, N. et al. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 29, 6773-6788 (2015).
7. Lu, R. M. et al. Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One. 8, e66128, https://doi.org/10.1371/journal.pone.0066128 (2013).
8. Muralidharan, R. et al. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 14, 47 (2016).
9. Yang, Y., Zhang, Y. M., Chen, Y., Chen, J. T. & Liu, Y. Polysaccharide-based Noncovalent Assembly for Targeted Delivery of Taxol. Sci Rep. 6, 19212, https://doi.org/10.1038/srep19212. (2016).
10. Guo, Y., Wang, L., Peng, L. V. & Zhang, P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett. 9, 1065-1072 (2015).
11. Shan, D. et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 5, 15-26 (2015).
12. Danhier, F., Breton, A. L. & Préat, V. RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Mol. Pharm. 9, 2961-2973 (2012).
13. Liu, Z., Wang, F. & Chen, X. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res. 69, 329-339 (2008).
14. Shukla, R. et al. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem. Commun. 2005, 5739-5741 (2005).
15. Teesalu, T., Sugahara, K. N. & Ruoslahti, E. Tumor-Penetrating Peptides. Front Oncol. 3, 216, https://doi.org/10.3389/fonc.2013.00216 (2013).
16. Schiffelers, R. M. et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 91, 115-122 (2003).
17. Gandioso, A., Cano, M., Massaguer, A. & Marchán, V. A Green Light-Triggerable RGD Peptide for Photocontrolled Targeted Drug Delivery: Synthesis and Photolysis Studies. J. Org. Chem. 81, 11556-11564 (2016).
18. Arosio, D., Manzoni, L., Araldi, E. M. & Scolastico, C. Cyclic RGD Functionalized Gold Nanoparticles for Tumor Targeting. Bioconjugate Chem. 22, 664-672 (2011).
19. Qu, X. et al. Micro-CT Imaging of RGD-Conjugated Gold Nanorods Targeting Tumor In Vivo. J Nanomater. 2016, 8368154, https://doi.org/10.1155/2016/8368154 (2016).
20. Damjanovich, L., Albelda, S. M., Mette, S. A. & Buck, C. A. Distribution of integrin cell adhesion receptors in normal and malignant lung tissue. Am J Respir Cell Mol Biol. 6, 197-206 (1992).
21. Singh, B., Fu, C. & Bhattacharya, J. Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. Am J Physiol Lung Cell Mol Physiol. 278, L217-226 (2000).
22. Zhang, X. et al. Tumor targeting strategies for chitosan-based nanoparticles. Colloids Surf B Biointerfaces. 148, 460-473 (2016).
23. Wang, Y., Li, P. & Kong, L. Chitosan-Modified PLGA Nanoparticles with Versatile Surface for Improved Drug Delivery. AAPS Pharm Sci Tech. 14, 585-592 (2013).
24. Manca, M. L., Mourtas, S., Dracopoulos, V., Fadda, A. M. & Antimisiaris, S. G. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery?: A comparative study of particle stability during nebulization. Colloids Surf B Biointerfaces. 62, 220-231 (2008).
25. Mufti, R. E. et al. Implications of αvβ3 Integrin Signaling in the Regulation of Ca2+ Waves and Myogenic Tone in Cerebral Arteries. Arterioscler Thromb Vasc Biol. 35, 2571-2578 (2015).
26. Kokkoli, E., Ochsenhirt, S. E. & Tirrell, M. Collective and single-molecule interactions of alpha5beta1 integrins. Langmuir. 20, 2397-2404 (2004).
27. Hautanen, A., Gailit, J., Mann, D. M. & Ruoslahti, E. Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. J Biol Chem. 264, 1437-1442 (1989).
28. De la Fuente, J. M., Berry, C. C., Riehle, M. O. & Curtis, A. S. G. Nanoparticle Targeting at Cells. Langmuir. 22, 3286-3293 (2006).
29. Qian, J. et al. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model. World J Gastroenterol. 22, 5042-5049 (2016).
30. Garg, A. & Kokkoli, E. pH-Sensitive PEGylated liposomes functionalized with a fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cell. Curr Pharm Biotechnol. 12, 1135-1143 (2011).
31. Garg, A., Tisdale, A. W., Haidari, E. & Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm. 366, 201-210 (2009).
32. Demirgöz, D., Garg, A. & Kokkoli, E. PR-b-targetedPEGylated liposomes for prostate cancer therapy. Langmuir. 24, 13518-13524 (2008).
33. Sharma, N., Madan, P. & Lin, S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study. Asian J Pharm Sci. 11, 404-416 (2016).
34. Cohen-Sela, E., Chorny, M., Koroukhov, N., Danenberg, H. D. & Golomb, G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release. 133, 90-95 (2009).
35. Chronopoulou, L. et al. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures. Colloids Surf B Biointerfaces 103, 310-317 (2013).
36. Pandit, J., Sultana, Y. & Aqil. M. Chitosan-Coated PLGA Nanoparticles of Bevacizumab as Novel Drug Delivery to Target Retina: Optimization, Characterization, and in Vitro Toxicity Evaluation. Artif Cells Nanomed Biotechnol. 1-11, https://doi.org/10.1080/21 691401.2016.1243545 (2016).
37. Zhao, K. et al. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine. Int J Nanomed. 9, 4609-4619, https://doi.org/10.2147/IJN.S70633 (2014).
38. Babu, A. et al. Chitosan coated poly(lactic acid) polymeric nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol. Pharm. 11, 2720-2733 (2014).
39. Lankveld, D. P. et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine (Lond). 6, 339-349 (2011).
40. Prapainop, K., Witter, D. P. & Wentworth, P. Jr. A chemical approach for cell-specific targeting of nanomaterials: small-moleculeinitiated misfolding of nanoparticle corona proteins. J Am Chem Soc. 134, 4100-3 (2012).
41. Mahmoudi, M. et al. Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine (Lond). 10, 215-26, https://doi.org/10.2217/nnm.14.69 (2015).
42. Cheng, J. et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869-76 (2007).
43. Su, Y. et al. Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance. Drug Des Devel Ther. 11, 659-668 (2017).
44. Makadia, H. K. & Siegel, S. J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 3, 1377-1397 (2011).
45. Alexis, F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym. Int. 54, 36-46 (2005).
46. Danhier, F. et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Control Release. 133, 11-17 (2009).
47. Modi, S. & Anderson, B. D. Determination of Drug Release Kinetics from Nanoparticles: Overcoming Pitfalls of the Dynamic Dialysis Method. Mol. Pharmaceutics 10, 3076-3089 (2013).
48. Zhang, Z. & Feng, S. S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27, 4025-4033 (2006).
49. Jin, C. et al. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res. 26, 1776-84 (2009).
50. Elias, D. R., Poloukhtine, A., Popik, V. & Tsourkas, A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine. 9, 194-201 (2013).
51. Suzuki, S. et al. Alterations of integrin expression in human lung cancer. Jpn J Cancer Res. 84, 168-174 (1993).
52. Zhan, C. et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release. 143, 136-142 (2010).
53. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine. 7, 5577-5591 (2012).
54. Yu, B., Zhang, Y., Zheng, W., Fan, C. & Chen, T. Positive Surface Charge Enhances Selective Cellular Uptake and Anticancer Efficacy of Selenium Nanoparticles. Inorg. Chem 51, 8956-8963 (2012).
55. Vilos, C. et al. Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials. 34, 4098-4108 (2013).
56. Das, G. C., Holiday, D., Gallardo, R. & Haas, C. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett. 165, 147-153 (2001).
57. Li, R., Moudgil, T., Ross, H. J. & Hu, H. M. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ. 12, 292-303 (2005).
58. Druškovič, M., Šuput, D. & Milisav, I. Overexpression of Caspase-9 Triggers Its Activation and Apoptosis in Vitro. Croat Med J. 47, 832-840 (2006).
59. Lee, H. H. et al. Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt. Oncol Rep. 31, 183-188 (2014).
60. Ajabnoor, G. M., Crook, T. & Coley, H. M. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis. 3, e260, https://doi.org/10.1038/cddis.2011.139 (2012).
61. Luo, X. & Kraus, W. L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 26, 417-432 (2012).
62. Mitchison, T. J. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell. 23, 1-6 (2012).
63. Payne, S. & Miles, D. Mechanisms of Anticancer Drugs, In Gleeson, M. (Ed.), Scott-Brown's Otorhinolaryngology: Head and Neck Surgery 7Ed. CRC Press, 34-46. https://doi.org/10.1201/b15118-6 (2008).
64. Ikeda, M. et al. DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. Int J Oncol. 36, 1081-1088 (2010).
65. Olive, P. L. & Banath, J. P. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry Part B. 76B, 79-90 (2009).
66. Mehta, M. et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 7, 64820-64835 (2016).
67. Schrump, D. S. et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J Thorac Cardiovasc Surg. 123, 686-694 (2002).
68. Lee, J. G. & Wu, R. Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PLoS One. 7, e48532, https://doi.org/10.1371/journal.pone.0048532 (2012).
69. Matsuoka, H., Furusawa, M., Tomoda, H. & Seo, Y. Difference in cytotoxicity of paclitaxel against neoplastic and normal cells. Anticancer Res. 14, 163-167 (2008).
70. Keum, C.-G. et al. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid. Int J Nanomed 6, 2225-2234 (2011).
71. Patil, Y. & Panyam, J. Polymeric Nanoparticles for siRNA Delivery and Gene Silencing. Int J Pharm. 367, 195-203 (2009).
72. Basotra, M., Singh, S. K. & Gulati, M. Development and Validation of a Simple and Sensitive Spectrometric Method for Estimation of Cisplatin Hydrochloride in Tablet Dosage Forms: Application to Dissolution Studies. ISRN Anal Chem. 2013, 936254, https://doi.org/10.1155/2013/936254 (2013).
73. Ramesh, R. et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 63, 5105-5113 (2003).
74. Zeng, R., Chen, Y., Zhao, S. & Cui, G. H. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol. Sin. 33, 91-100 (2012).
75. Srivastava, A. et al. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 6, 38541 (2016).